Share Price and Basic Stock Data
Last Updated: January 3, 2026, 11:52 am
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Mangalam Drugs and Organics Ltd operates within the pharmaceuticals sector, focusing on the production of various pharmaceutical products. As of the latest reporting, the company’s stock price stood at ₹30.3 with a market capitalization of ₹47.9 Cr. The company reported sales of ₹372 Cr for FY 2023, which declined to ₹369 Cr in FY 2024 and further to ₹318 Cr in FY 2025, indicating a downward trend in revenue generation. Quarterly sales figures also reflected volatility, with a peak of ₹108.33 Cr in September 2022, followed by a decline to ₹81.56 Cr in September 2023. Despite these fluctuations, the company recorded a sales figure of ₹269 Cr for the trailing twelve months (TTM), suggesting a continued challenge in maintaining revenue growth. The operating profit margin (OPM) for FY 2023 was reported at 7%, which declined to 5% in FY 2024, underlining the difficulties faced in managing operational costs amidst fluctuating sales. Overall, the revenue trajectory indicates significant challenges that the company needs to address to stabilize its financial performance.
Profitability and Efficiency Metrics
Mangalam Drugs and Organics Ltd’s profitability metrics reveal a concerning trend with negative net profits reported in several quarters. The net profit for FY 2023 was a mere ₹1 Cr, declining to a loss of ₹9 Cr in FY 2024, followed by a small profit of ₹7 Cr in FY 2025. Quarterly results reflect similar volatility, with a net profit of ₹2.23 Cr in September 2022 deteriorating to a loss of ₹9.54 Cr by June 2023. The return on equity (ROE) stood at 4.71%, while the return on capital employed (ROCE) was reported at 8.03%, both of which are relatively low compared to sector averages. The company’s operational efficiency is also demonstrated by its cash conversion cycle (CCC) of 148 days, indicating a longer duration to convert investments in inventory and receivables back into cash. This prolonged CCC reflects inefficiencies that may hinder profitability and cash flow management. Overall, the company’s profitability and efficiency metrics highlight the need for strategic initiatives to enhance operational performance and financial health.
Balance Sheet Strength and Financial Ratios
The balance sheet of Mangalam Drugs and Organics Ltd shows a mixed picture of financial strength. As of the latest reporting, the company reported total borrowings of ₹95 Cr against reserves of ₹112 Cr, leading to a debt-to-equity ratio of 0.54, which is moderate compared to industry standards. The interest coverage ratio (ICR) stood at 2.43x, indicating that the company generates sufficient operating profit to cover its interest obligations, albeit with limited buffer. The book value per share increased from ₹85.79 in FY 2024 to ₹94.12 in FY 2025, reflecting a modest improvement in shareholder equity. However, the price-to-book value (P/BV) ratio of 0.78x suggests that the stock is trading below its intrinsic value compared to its book value. The company’s total assets were reported at ₹359 Cr, with fixed assets amounting to ₹156 Cr, indicating a solid asset base, yet the challenges in profitability and revenue generation raise concerns about the effective utilization of these assets.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Mangalam Drugs and Organics Ltd reveals a stable promoter holding at 50.30%, indicating a strong commitment from the management. Foreign institutional investors (FIIs) held a minimal stake of 0.11%, suggesting limited foreign interest in the company, which could reflect investor sentiment about its growth prospects. The public holding stands at 49.57%, with a total of 19,881 shareholders as of September 2025, showing a diversified ownership base. This distribution may provide some stability, but the low FII participation indicates a lack of confidence from institutional investors. The company’s dividend payout has remained at 0%, which may further deter income-focused investors. Overall, the shareholding structure points to a committed yet cautious investor base, highlighting the need for the company to enhance its financial performance to attract broader investor interest.
Outlook, Risks, and Final Insight
The outlook for Mangalam Drugs and Organics Ltd is contingent upon its ability to address profitability challenges and operational inefficiencies. The persistent negative net profits and declining revenue trends pose significant risks to its financial stability. Additionally, the extended cash conversion cycle indicates potential liquidity issues that could affect day-to-day operations. On the other hand, the company’s stable promoter holding and improving book value per share present some strengths that could be leveraged for future growth. The management may need to implement strategic measures to streamline operations, reduce costs, and improve revenue generation. In a scenario where the company successfully enhances its operational efficiency and profitability, it could attract more investor interest, potentially improving its market valuation. Conversely, failure to address these issues may lead to a decline in investor confidence and further financial distress.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 133 Cr. | 106 | 216/84.3 | 29.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,742 Cr. | 435 | 479/192 | 98.2 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.3 Cr. | 47.6 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 53.6 Cr. | 36.6 | 37.0/17.0 | 128 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,248.81 Cr | 1,149.28 | 54.07 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 108.33 | 63.32 | 91.11 | 87.46 | 81.56 | 97.34 | 102.24 | 76.53 | 79.94 | 88.71 | 73.04 | 57.35 | 49.54 |
| Expenses | 99.89 | 56.84 | 90.87 | 90.94 | 79.37 | 90.36 | 90.54 | 68.34 | 71.25 | 79.94 | 62.88 | 61.86 | 52.37 |
| Operating Profit | 8.44 | 6.48 | 0.24 | -3.48 | 2.19 | 6.98 | 11.70 | 8.19 | 8.69 | 8.77 | 10.16 | -4.51 | -2.83 |
| OPM % | 7.79% | 10.23% | 0.26% | -3.98% | 2.69% | 7.17% | 11.44% | 10.70% | 10.87% | 9.89% | 13.91% | -7.86% | -5.71% |
| Other Income | 0.00 | 0.13 | 0.29 | 0.02 | 0.03 | 0.00 | 0.05 | 0.02 | 0.14 | 0.13 | 0.21 | 0.00 | 0.03 |
| Interest | 2.56 | 3.22 | 3.43 | 3.41 | 3.24 | 3.31 | 3.95 | 3.75 | 3.67 | 3.49 | 4.03 | 4.04 | 5.03 |
| Depreciation | 2.76 | 2.88 | 2.75 | 3.42 | 3.73 | 3.62 | 3.86 | 3.87 | 3.97 | 3.93 | 4.61 | 4.38 | 4.53 |
| Profit before tax | 3.12 | 0.51 | -5.65 | -10.29 | -4.75 | 0.05 | 3.94 | 0.59 | 1.19 | 1.48 | 1.73 | -12.93 | -12.36 |
| Tax % | 28.85% | 15.69% | -22.30% | -7.29% | -25.05% | -920.00% | 9.90% | -355.93% | -125.21% | 5.41% | 90.75% | 6.19% | -41.42% |
| Net Profit | 2.23 | 0.43 | -4.39 | -9.54 | -3.56 | 0.50 | 3.55 | 2.68 | 2.69 | 1.40 | 0.15 | -13.73 | -7.25 |
| EPS in Rs | 1.41 | 0.27 | -2.77 | -6.03 | -2.25 | 0.32 | 2.24 | 1.69 | 1.70 | 0.88 | 0.09 | -8.67 | -4.58 |
Last Updated: December 30, 2025, 1:37 am
Below is a detailed analysis of the quarterly data for Mangalam Drugs and Organics Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 49.54 Cr.. The value appears to be declining and may need further review. It has decreased from 57.35 Cr. (Jun 2025) to 49.54 Cr., marking a decrease of 7.81 Cr..
- For Expenses, as of Sep 2025, the value is 52.37 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 61.86 Cr. (Jun 2025) to 52.37 Cr., marking a decrease of 9.49 Cr..
- For Operating Profit, as of Sep 2025, the value is -2.83 Cr.. The value appears strong and on an upward trend. It has increased from -4.51 Cr. (Jun 2025) to -2.83 Cr., marking an increase of 1.68 Cr..
- For OPM %, as of Sep 2025, the value is -5.71%. The value appears strong and on an upward trend. It has increased from -7.86% (Jun 2025) to -5.71%, marking an increase of 2.15%.
- For Other Income, as of Sep 2025, the value is 0.03 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Jun 2025) to 0.03 Cr., marking an increase of 0.03 Cr..
- For Interest, as of Sep 2025, the value is 5.03 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.04 Cr. (Jun 2025) to 5.03 Cr., marking an increase of 0.99 Cr..
- For Depreciation, as of Sep 2025, the value is 4.53 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.38 Cr. (Jun 2025) to 4.53 Cr., marking an increase of 0.15 Cr..
- For Profit before tax, as of Sep 2025, the value is -12.36 Cr.. The value appears strong and on an upward trend. It has increased from -12.93 Cr. (Jun 2025) to -12.36 Cr., marking an increase of 0.57 Cr..
- For Tax %, as of Sep 2025, the value is -41.42%. The value appears to be improving (decreasing) as expected. It has decreased from 6.19% (Jun 2025) to -41.42%, marking a decrease of 47.61%.
- For Net Profit, as of Sep 2025, the value is -7.25 Cr.. The value appears strong and on an upward trend. It has increased from -13.73 Cr. (Jun 2025) to -7.25 Cr., marking an increase of 6.48 Cr..
- For EPS in Rs, as of Sep 2025, the value is -4.58. The value appears strong and on an upward trend. It has increased from -8.67 (Jun 2025) to -4.58, marking an increase of 4.09.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:00 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 123 | 221 | 295 | 299 | 269 | 228 | 282 | 380 | 451 | 372 | 369 | 318 | 269 |
| Expenses | 113 | 200 | 257 | 252 | 222 | 218 | 259 | 327 | 402 | 347 | 351 | 282 | 257 |
| Operating Profit | 10 | 20 | 38 | 47 | 47 | 10 | 24 | 53 | 49 | 26 | 17 | 36 | 12 |
| OPM % | 8% | 9% | 13% | 16% | 17% | 4% | 8% | 14% | 11% | 7% | 5% | 11% | 4% |
| Other Income | 0 | 0 | 0 | -0 | 1 | 0 | 1 | 5 | 0 | 0 | 0 | 0 | 0 |
| Interest | 10 | 10 | 9 | 10 | 12 | 9 | 10 | 9 | 11 | 13 | 14 | 15 | 17 |
| Depreciation | 4 | 4 | 4 | 5 | 7 | 7 | 8 | 9 | 10 | 11 | 15 | 16 | 17 |
| Profit before tax | -4 | 6 | 24 | 31 | 29 | -6 | 6 | 40 | 28 | 2 | -11 | 5 | -22 |
| Tax % | -22% | -2% | 33% | 29% | 32% | 40% | -32% | 29% | 29% | 43% | -18% | -39% | |
| Net Profit | -3 | 6 | 16 | 22 | 20 | -8 | 8 | 28 | 20 | 1 | -9 | 7 | -19 |
| EPS in Rs | -2.31 | 4.66 | 11.15 | 14.08 | 12.57 | -5.07 | 5.21 | 17.67 | 12.42 | 0.80 | -5.72 | 4.37 | -12.28 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 4% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 300.00% | 166.67% | 37.50% | -9.09% | -140.00% | 200.00% | 250.00% | -28.57% | -95.00% | -1000.00% | 177.78% |
| Change in YoY Net Profit Growth (%) | 0.00% | -133.33% | -129.17% | -46.59% | -130.91% | 340.00% | 50.00% | -278.57% | -66.43% | -905.00% | 1177.78% |
Mangalam Drugs and Organics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
No data available for the compounded sales growth chart.
Balance Sheet
Last Updated: December 4, 2025, 1:37 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 14 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 10 | 16 | 47 | 70 | 88 | 80 | 88 | 115 | 135 | 136 | 127 | 133 | 112 |
| Borrowings | 77 | 78 | 60 | 66 | 69 | 65 | 52 | 70 | 88 | 89 | 107 | 96 | 95 |
| Other Liabilities | 25 | 63 | 38 | 38 | 54 | 50 | 75 | 64 | 90 | 117 | 108 | 114 | 87 |
| Total Liabilities | 125 | 170 | 160 | 190 | 227 | 211 | 231 | 264 | 328 | 358 | 357 | 359 | 310 |
| Fixed Assets | 53 | 53 | 54 | 93 | 102 | 103 | 101 | 118 | 135 | 142 | 147 | 156 | 152 |
| CWIP | 0 | 0 | 5 | 0 | 0 | 0 | 1 | 6 | 6 | 9 | 8 | 3 | 4 |
| Investments | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 72 | 117 | 100 | 95 | 125 | 107 | 128 | 140 | 188 | 206 | 202 | 201 | 155 |
| Total Assets | 125 | 170 | 160 | 190 | 227 | 211 | 231 | 264 | 328 | 358 | 357 | 359 | 310 |
Below is a detailed analysis of the balance sheet data for Mangalam Drugs and Organics Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 16.00 Cr..
- For Reserves, as of Sep 2025, the value is 112.00 Cr.. The value appears to be declining and may need further review. It has decreased from 133.00 Cr. (Mar 2025) to 112.00 Cr., marking a decrease of 21.00 Cr..
- For Borrowings, as of Sep 2025, the value is 95.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 96.00 Cr. (Mar 2025) to 95.00 Cr., marking a decrease of 1.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 87.00 Cr.. The value appears to be improving (decreasing). It has decreased from 114.00 Cr. (Mar 2025) to 87.00 Cr., marking a decrease of 27.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 310.00 Cr.. The value appears to be improving (decreasing). It has decreased from 359.00 Cr. (Mar 2025) to 310.00 Cr., marking a decrease of 49.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 152.00 Cr.. The value appears to be declining and may need further review. It has decreased from 156.00 Cr. (Mar 2025) to 152.00 Cr., marking a decrease of 4.00 Cr..
- For CWIP, as of Sep 2025, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2025) to 4.00 Cr., marking an increase of 1.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 155.00 Cr.. The value appears to be declining and may need further review. It has decreased from 201.00 Cr. (Mar 2025) to 155.00 Cr., marking a decrease of 46.00 Cr..
- For Total Assets, as of Sep 2025, the value is 310.00 Cr.. The value appears to be declining and may need further review. It has decreased from 359.00 Cr. (Mar 2025) to 310.00 Cr., marking a decrease of 49.00 Cr..
Notably, the Reserves (112.00 Cr.) exceed the Borrowings (95.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -67.00 | -58.00 | -22.00 | -19.00 | -22.00 | -55.00 | -28.00 | -17.00 | -39.00 | -63.00 | -90.00 | -60.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 88 | 73 | 37 | 45 | 61 | 28 | 52 | 52 | 38 | 46 | 28 | 45 |
| Inventory Days | 170 | 134 | 85 | 69 | 132 | 175 | 121 | 85 | 139 | 200 | 185 | 303 |
| Days Payable | 97 | 128 | 37 | 38 | 82 | 77 | 106 | 63 | 65 | 139 | 124 | 199 |
| Cash Conversion Cycle | 161 | 79 | 85 | 75 | 111 | 126 | 67 | 74 | 112 | 107 | 88 | 148 |
| Working Capital Days | 29 | 26 | 32 | 19 | 31 | 21 | 10 | 23 | 43 | 38 | 18 | 13 |
| ROCE % | 6% | 16% | 29% | 31% | 25% | 2% | 11% | 27% | 18% | 6% | 1% | 8% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 |
|---|---|---|
| FaceValue | 10.00 | 10.00 |
| Basic EPS (Rs.) | 4.25 | -5.73 |
| Diluted EPS (Rs.) | 4.25 | -5.73 |
| Cash EPS (Rs.) | 14.74 | 3.52 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 94.12 | 85.79 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 94.12 | 85.79 |
| Revenue From Operations / Share (Rs.) | 201.05 | 232.87 |
| PBDIT / Share (Rs.) | 22.95 | 11.05 |
| PBIT / Share (Rs.) | 12.46 | 1.80 |
| PBT / Share (Rs.) | 3.02 | -7.00 |
| Net Profit / Share (Rs.) | 4.25 | -5.73 |
| NP After MI And SOA / Share (Rs.) | 4.25 | -5.73 |
| PBDIT Margin (%) | 11.41 | 4.74 |
| PBIT Margin (%) | 6.19 | 0.77 |
| PBT Margin (%) | 1.50 | -3.00 |
| Net Profit Margin (%) | 2.11 | -2.46 |
| NP After MI And SOA Margin (%) | 2.11 | -2.46 |
| Return on Networth / Equity (%) | 4.51 | -6.68 |
| Return on Capital Employeed (%) | 11.27 | 1.67 |
| Return On Assets (%) | 1.83 | -2.71 |
| Long Term Debt / Equity (X) | 0.06 | 0.09 |
| Total Debt / Equity (X) | 0.54 | 0.64 |
| Asset Turnover Ratio (%) | 0.90 | 0.00 |
| Current Ratio (X) | 1.04 | 1.07 |
| Quick Ratio (X) | 0.31 | 0.31 |
| Inventory Turnover Ratio (X) | 2.43 | 0.00 |
| Interest Coverage Ratio (X) | 2.43 | 1.26 |
| Interest Coverage Ratio (Post Tax) (X) | 1.45 | 0.34 |
| Enterprise Value (Cr.) | 196.06 | 233.41 |
| EV / Net Operating Revenue (X) | 0.61 | 0.63 |
| EV / EBITDA (X) | 5.40 | 13.34 |
| MarketCap / Net Operating Revenue (X) | 0.36 | 0.39 |
| Price / BV (X) | 0.78 | 1.08 |
| Price / Net Operating Revenue (X) | 0.36 | 0.39 |
| EarningsYield | 0.05 | -0.06 |
After reviewing the key financial ratios for Mangalam Drugs and Organics Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 4.25. This value is below the healthy minimum of 5. It has increased from -5.73 (Mar 24) to 4.25, marking an increase of 9.98.
- For Diluted EPS (Rs.), as of Mar 25, the value is 4.25. This value is below the healthy minimum of 5. It has increased from -5.73 (Mar 24) to 4.25, marking an increase of 9.98.
- For Cash EPS (Rs.), as of Mar 25, the value is 14.74. This value is within the healthy range. It has increased from 3.52 (Mar 24) to 14.74, marking an increase of 11.22.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 94.12. It has increased from 85.79 (Mar 24) to 94.12, marking an increase of 8.33.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 94.12. It has increased from 85.79 (Mar 24) to 94.12, marking an increase of 8.33.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 201.05. It has decreased from 232.87 (Mar 24) to 201.05, marking a decrease of 31.82.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 22.95. This value is within the healthy range. It has increased from 11.05 (Mar 24) to 22.95, marking an increase of 11.90.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.46. This value is within the healthy range. It has increased from 1.80 (Mar 24) to 12.46, marking an increase of 10.66.
- For PBT / Share (Rs.), as of Mar 25, the value is 3.02. This value is within the healthy range. It has increased from -7.00 (Mar 24) to 3.02, marking an increase of 10.02.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 4.25. This value is within the healthy range. It has increased from -5.73 (Mar 24) to 4.25, marking an increase of 9.98.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 4.25. This value is within the healthy range. It has increased from -5.73 (Mar 24) to 4.25, marking an increase of 9.98.
- For PBDIT Margin (%), as of Mar 25, the value is 11.41. This value is within the healthy range. It has increased from 4.74 (Mar 24) to 11.41, marking an increase of 6.67.
- For PBIT Margin (%), as of Mar 25, the value is 6.19. This value is below the healthy minimum of 10. It has increased from 0.77 (Mar 24) to 6.19, marking an increase of 5.42.
- For PBT Margin (%), as of Mar 25, the value is 1.50. This value is below the healthy minimum of 10. It has increased from -3.00 (Mar 24) to 1.50, marking an increase of 4.50.
- For Net Profit Margin (%), as of Mar 25, the value is 2.11. This value is below the healthy minimum of 5. It has increased from -2.46 (Mar 24) to 2.11, marking an increase of 4.57.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 2.11. This value is below the healthy minimum of 8. It has increased from -2.46 (Mar 24) to 2.11, marking an increase of 4.57.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.51. This value is below the healthy minimum of 15. It has increased from -6.68 (Mar 24) to 4.51, marking an increase of 11.19.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.27. This value is within the healthy range. It has increased from 1.67 (Mar 24) to 11.27, marking an increase of 9.60.
- For Return On Assets (%), as of Mar 25, the value is 1.83. This value is below the healthy minimum of 5. It has increased from -2.71 (Mar 24) to 1.83, marking an increase of 4.54.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 0.2. It has decreased from 0.09 (Mar 24) to 0.06, marking a decrease of 0.03.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.54. This value is within the healthy range. It has decreased from 0.64 (Mar 24) to 0.54, marking a decrease of 0.10.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.90. It has increased from 0.00 (Mar 24) to 0.90, marking an increase of 0.90.
- For Current Ratio (X), as of Mar 25, the value is 1.04. This value is below the healthy minimum of 1.5. It has decreased from 1.07 (Mar 24) to 1.04, marking a decrease of 0.03.
- For Quick Ratio (X), as of Mar 25, the value is 0.31. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.31.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.43. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 2.43, marking an increase of 2.43.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.43. This value is below the healthy minimum of 3. It has increased from 1.26 (Mar 24) to 2.43, marking an increase of 1.17.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 3. It has increased from 0.34 (Mar 24) to 1.45, marking an increase of 1.11.
- For Enterprise Value (Cr.), as of Mar 25, the value is 196.06. It has decreased from 233.41 (Mar 24) to 196.06, marking a decrease of 37.35.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.61. This value is below the healthy minimum of 1. It has decreased from 0.63 (Mar 24) to 0.61, marking a decrease of 0.02.
- For EV / EBITDA (X), as of Mar 25, the value is 5.40. This value is within the healthy range. It has decreased from 13.34 (Mar 24) to 5.40, marking a decrease of 7.94.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.36. This value is below the healthy minimum of 1. It has decreased from 0.39 (Mar 24) to 0.36, marking a decrease of 0.03.
- For Price / BV (X), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 1. It has decreased from 1.08 (Mar 24) to 0.78, marking a decrease of 0.30.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.36. This value is below the healthy minimum of 1. It has decreased from 0.39 (Mar 24) to 0.36, marking a decrease of 0.03.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from -0.06 (Mar 24) to 0.05, marking an increase of 0.11.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Mangalam Drugs and Organics Ltd:
- Net Profit Margin: 2.11%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.27% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.51% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.45
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.31
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 54.07)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.54
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.11%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Rupam Building, 3rd Floor, Mumbai Maharashtra 400001 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Govardhan Murlidhar Dhoot | Chairman & Managing Director |
| Mr. Brijmohan Murlidhar Dhoot | Whole Time Director |
| Mr. Praveen Saxena | Independent Director |
| Mr. Rakesh Kishinchand Milwani | Non Exe.Non Ind.Director |
| Mr. Rukmesh Prabhukumar Dhandhania | Independent Director |
| Mrs. Nidhi Shantanu Mundada | Independent Director |
FAQ
What is the intrinsic value of Mangalam Drugs and Organics Ltd?
Mangalam Drugs and Organics Ltd's intrinsic value (as of 03 January 2026) is ₹46.41 which is 53.17% higher the current market price of ₹30.30, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹48.0 Cr. market cap, FY2025-2026 high/low of ₹130/22.7, reserves of ₹112 Cr, and liabilities of ₹310 Cr.
What is the Market Cap of Mangalam Drugs and Organics Ltd?
The Market Cap of Mangalam Drugs and Organics Ltd is 48.0 Cr..
What is the current Stock Price of Mangalam Drugs and Organics Ltd as on 03 January 2026?
The current stock price of Mangalam Drugs and Organics Ltd as on 03 January 2026 is ₹30.3.
What is the High / Low of Mangalam Drugs and Organics Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Mangalam Drugs and Organics Ltd stocks is ₹130/22.7.
What is the Stock P/E of Mangalam Drugs and Organics Ltd?
The Stock P/E of Mangalam Drugs and Organics Ltd is .
What is the Book Value of Mangalam Drugs and Organics Ltd?
The Book Value of Mangalam Drugs and Organics Ltd is 80.5.
What is the Dividend Yield of Mangalam Drugs and Organics Ltd?
The Dividend Yield of Mangalam Drugs and Organics Ltd is 0.00 %.
What is the ROCE of Mangalam Drugs and Organics Ltd?
The ROCE of Mangalam Drugs and Organics Ltd is 8.03 %.
What is the ROE of Mangalam Drugs and Organics Ltd?
The ROE of Mangalam Drugs and Organics Ltd is 4.71 %.
What is the Face Value of Mangalam Drugs and Organics Ltd?
The Face Value of Mangalam Drugs and Organics Ltd is 10.0.